Admission to trading on OTCQB in the US
Abingdon Health plc has announced the admission of its ordinary shares to trading on the OTCQB Venture Market in the United States under the ticker symbol ABDXF, effective today. This listing on the OTCQB is designed for development stage companies and, as a foreign private issuer, Abingdon Health will not face additional reporting obligations or incur significant extra costs due to its exemption under US Exchange Act Rule 12g3-2(b), provided it continues to make information available to US investors in English as required by its home market regulator. The company's ordinary shares will continue to trade on the London Stock Exchange's AIM Market under the symbol ABDX.
Select text to share a quote on X · sign in to keep highlights & notes in your ABDX notes
York, UK and Madison, WI, USA, 21 April 2026: Abingdon Health plc (AIM: ABDX) (OTCQB: ABDXF), a leading international developer, manufacturer and regulatory services provider for rapid diagnostic tests and med-tech, announces that trading in the Company's ordinary shares will begin today at 9.30am EST on the OTCQB Venture Market ("OTCQB") in the United States, under the ticker symbol "ABDXF".
The OTCQB is designed for entrepreneurial and development stage US and international companies. Foreign Private Issuers, such as Abingdon Health, that trade on the OTCQB are exempt under the US Exchange Act Rule 12g3-2(b) from SEC reporting if they make whatever information is required by their home market regulator publicly available to US investors in English. Abingdon Health will therefore face no extra reporting obligations and incur minimal ongoing costs as a result of the Company's Ordinary Shares being traded on the OTCQB.
Abingdon Health's Ordinary Shares will continue to trade on the London Stock Exchange's AIM Market under the symbol "ABDX".
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.